William Harris, MD
Medical Oncology · Seattle, WANPI 1508980194
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 69.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $13,582 and has fallen 83.5% since, to $2,240 in 2025.
Across 36 payments — averaging $1057.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$26K
- Eisai Inc.$4K
- Servier Pharmaceuticals LLC$2K
- Astrazeneca UK Limited$2K
- Bard Peripheral Vascular, Inc.$1K
- AstraZeneca$1K
- plus $758 from 4 others
Across 439 payments — averaging $4509.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$744K
- AstraZeneca$261K
- Agios Pharmaceuticals, Inc.$209K
- Exelixis Inc.$181K
- Sanofi US Services Inc.$174K
- Halozyme Inc$126K
- plus $284K from 8 others
What the payments were for
- Consulting fees$17,97147%
- Speaking & faculty fees$15,75141%
- Travel & lodging$1,2213%
- Food & beverage$3,1228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $26,410 |
| Eisai Inc. | 3 | $4,183 |
| Servier Pharmaceuticals LLC | 2 | $1,971 |
| Astrazeneca UK Limited | 1 | $1,925 |
| Bard Peripheral Vascular, Inc. | 1 | $1,438 |
| AstraZeneca | 3 | $1,381 |
| Pfizer | 2 | $465 |
| Genentech USA, Inc. | 1 | $143 |
| E.r. Squibb & Sons, L.L.C. | 1 | $100 |
| Servier Bioinnovation | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$11,167
- TheraSphere Y90 Glass Microspheres 10 GBq$5,865
- LENVIMA$4,183
- GENERAL PAIN MANAGEMENT$2,400
- TIBSOVO$1,971
- IMFINZI$731
- GENERAL ONCOLOGY$600
- TECENTRIQ$143
- PADCEV$135
How this compares
$38,064 in reported general payments places this provider in the 80th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 12 | $2,202 |
| Prochlorperazine Maleate | 25 | $561 |
| Ondansetron Hcl | 27 | $378 |
| LoperamideLoperamide Hcl | 18 | $239 |
| Dexamethasone | 23 | $119 |
| Amlodipine Besylate | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.